Step 1 Inclusion Criteria:

          -  Provision of signed and dated informed consent form for Step 1

          -  Male or female, aged 18 years and older

          -  Diagnosed with adenocarcinoma of the pancreas deemed to be potentially resectable and
             who are deemed to be good candidates for adjuvant and/or neoadjuvant chemotherapy.
             This may include patients whose tumors are deemed suitable for upfront resection as
             well as patients whose tumors are deemed borderline resectable and thus undergo
             neoadjuvant therapy prior to resection. Note: women of child-bearing potential must be
             on birth control for 30 days prior to first vaccination; it is recommended to discuss
             this requirement with subjects at Step 1.

        Step 1 Exclusion Criteria:

          -  Unresectable or metastatic (stage IV) pancreatic cancer

          -  Patients with known HIV positivity

          -  Patients with active HBV and HCV infection. Those who are Hepatitis B sAb positive as
             well as those who are Hepatitis C Ab positive but Hepatitis C RNA viral load negative
             will not be excluded.

          -  Patients with active of autoimmune disease or immune deficiency or previous
             Guillain-Barre syndrome. Patients with eczema, psoriasis, lichen simplex chronicus or
             vitiligo with dermatologic manifestations only (e.g. patient with psoriatic arthritis
             are excluded) are eligible provided all of the following conditions are met: rash must
             cover < 10% of body surface area; disease is well controlled at baseline and requires
             only low-potency topical corticosteroids; no occurrence of acute exacerbations of the
             underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate,
             retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral
             corticosteroids within the previous 12 months.

        Step 2 Inclusion Criteria:

          -  Provision of signed and dated informed consent form for Step 2

          -  Must have completed standard neo-adjuvant and/or adjuvant chemotherapy and surgery, as
             deemed by Investigator.

          -  Must have completed standard care within 6 weeks of step 2 registration.

          -  Must have adequate tissue obtained from surgery, as determined and confirmed by Dr.
             Decker.

          -  Adequate kidney, liver, bone marrow function, and immune function, as follows, within
             28 days prior to step 2 registration: Hemoglobin greater than/equal to 8 gm/dL;
             Absolute neutrophil count (ANC) greater than/equal to 1,500 cells/mm3; Platelet count
             greater than/equal to 75,000/mm3; Total bilirubin less than/equal to 1.5 times upper
             limit of normal (ULN); Aspartate transaminase AST (SGOT) and alanine aminotransferase
             ALT (SGPT) less than/equal to 2.5 times the ULN; TSH range between 0.4-4.0 mIU/L; RF
             less than/equal to 15 IU/ml; Peripheral CD4+ t-cell greater than 200/ul.

          -  Negative Hepatitis B and C serology. Positive HBs Ab indicating immunity is not
             exclusionary. Those who are Hepatitis B sAb positive as well as those who are
             Hepatitis C Ab positive but Hepatitis C RNA viral load negative will not be excluded.

          -  ECOG performance status less than/equal to 2

          -  For women of child bearing potential (WOCBP): At the time or (or prior to)
             registration to Step 2, use of highly effective contraception must be discussed with
             participant. NOTE: Patient must agree to start contraception at least 30 days before
             first vaccination and continue for at least 12 weeks after his/her last vaccination.

          -  WOCBP must have a negative serum pregnancy within 28 days of registration to step 2.

          -  For males of reproductive potential: use of condoms or other methods to ensure
             effective contraception with partner during study participation and for an additional
             12 weeks following discontinuations of last vaccination.

          -  Patient must agree to not donate blood for up to 90 days after last vaccination.

        Step 2 Exclusion Criteria:

          -  Use of nonstandard adjuvant chemotherapy regimen, as determined by the Investigator.

          -  Female patients who are pregnant, breast feeding, or of childbearing potential without
             a negative pregnancy test within 28 days of registration to Step 2 (or decline
             contraception requirements as outlined above). Post-menopausal women must be
             amenorrheic for at least 12 months to be considered of non-childbearing potential.

          -  Patients unwilling or unable to comply with the protocol or provide informed consent.

          -  Any severe or uncontrolled medical condition or other condition that could affect
             participation in this study (in the opinion of the investigator), including but not
             limited to: hyper/hypothyroidism, active systemic autoimmune disorders, untreated
             viral hepatitis or autoimmune hepatitis.

          -  Treatment with a systemic steroid or with any systemic immunosuppressive agent within
             7 days of step 2 registration.